Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma.
Edgar G KozlovaHsin-Hui HuangOpeyemi A JagedeKevin TuballesDiane M Del ValleGeoffrey KellyManishkumar PatelHui XieJocelyn HarrisKimberly ArguetaKai NieVanessa BarcessatRadim MoravecJennifer AltreuterDzifa Yawa DuoseBrad S KahlStephen M AnsellJoyce YuEthan CeramiJames R LindsayIgnacio I WistubaSeunghee Kim-SchulzeCatherine S DiefenbachSacha GnjaticPublished in: Cancer research communications (2024)
Identification of multi-omic immune markers from peripheral blood may help elucidate resistance mechanisms to checkpoint inhibitor and antibody-drug conjugate combinations with potential implications for treatment decisions in relapsed HL.